CN101106985A - 20－环烷基，26,27－烷基/卤代烷基维生素d3化合物及其使用方法 - Google Patents

20－环烷基，26,27－烷基/卤代烷基维生素d3化合物及其使用方法 Download PDF

Info

Publication number
CN101106985A
CN101106985A CNA2005800401650A CN200580040165A CN101106985A CN 101106985 A CN101106985 A CN 101106985A CN A2005800401650 A CNA2005800401650 A CN A2005800401650A CN 200580040165 A CN200580040165 A CN 200580040165A CN 101106985 A CN101106985 A CN 101106985A
Authority
CN
China
Prior art keywords
chemical compound
vitamin
described method
cyclopropyl
cholecalciferol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800401650A
Other languages
English (en)
Chinese (zh)
Inventor
M·R·乌斯科科维克
L·阿多里尼
G·彭纳
E·科利
S·马查克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxell SpA
Original Assignee
Bioxell SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxell SpA filed Critical Bioxell SpA
Publication of CN101106985A publication Critical patent/CN101106985A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
CNA2005800401650A 2004-09-24 2005-09-23 20－环烷基，26,27－烷基/卤代烷基维生素d3化合物及其使用方法 Pending CN101106985A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61273204P 2004-09-24 2004-09-24
US60/612,732 2004-09-24

Publications (1)

Publication Number Publication Date
CN101106985A true CN101106985A (zh) 2008-01-16

Family

ID=36119461

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800401650A Pending CN101106985A (zh) 2004-09-24 2005-09-23 20－环烷基，26,27－烷基/卤代烷基维生素d3化合物及其使用方法

Country Status (9)

Country Link
US (1) US20080318911A1 (https=)
EP (1) EP1797033A4 (https=)
JP (1) JP2008514621A (https=)
CN (1) CN101106985A (https=)
AU (1) AU2005289664A1 (https=)
CA (1) CA2580962A1 (https=)
IL (1) IL182145A0 (https=)
WO (1) WO2006036813A2 (https=)
ZA (1) ZA200703310B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180293A (zh) * 2010-10-25 2013-06-26 帝人制药株式会社 23-炔-维生素d3衍生物
CN103193695A (zh) * 2013-04-22 2013-07-10 中国药科大学 3-苯基-3-吡咯基戊烷类衍生物及其医药用途
CN113274346A (zh) * 2021-05-25 2021-08-20 满孝勇 一种莫匹罗星软膏的应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134286A1 (en) * 2004-12-02 2007-06-14 Wu-Wong Jinshyun R Methods for reducing intimal hyperplasia, smooth muscle cell proliferation and restenosis in mammals
US7286295B1 (en) 2005-11-30 2007-10-23 Sandia Corporation Microoptical compound lens
WO2009115398A1 (en) * 2008-03-18 2009-09-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Vitamin d compounds for the treatment of biliary diseases
DE602010000019D1 (de) * 2009-05-20 2011-05-26 Hybrigenics Sa Neue therapeutische Verwendungen von Inecalcitol
EP2682386B1 (en) * 2011-03-02 2016-08-17 Nihon University Novel vitamin d receptor modulator with partial agonist activity
US9370527B2 (en) 2012-12-28 2016-06-21 The Regents Of The University Of Michigan Amelioration of intestinal fibrosis and treatment of Crohn's disease
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
MX2022001756A (es) * 2019-08-13 2022-05-18 Tohoku Techno Arch Co Ltd Inhibidor del punto de control inmunitario, agente terapeutico para la enfermedad relacionada con el punto de control inmunitario, inmunosupresor, anticuerpo contra la fibronectina o derivado del mismo, analogo de la fibronectina, kit para detectar la fibronectina o una proteina parcial de la misma, y metodo para detectar la fibronectina o una proteina parcial de la misma.
PH12022551462A1 (en) 2019-12-19 2023-11-13 Ngm Biopharmaceuticals Inc Ilt3-binding agents and methods of use thereof
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
SG70010A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Fluorinated vitamin d3 analogs
AU743514B2 (en) * 1997-05-16 2002-01-24 Women & Infants Hospital Cyclic ether vitamin D3 compounds, 1alpha (OH) 3-EPI-vitamin D3 compounds and uses thereof
WO1999012894A1 (en) * 1997-09-08 1999-03-18 F. Hoffmann-La Roche Ag 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analogs
US6331642B1 (en) * 1999-07-12 2001-12-18 Hoffmann-La Roche Inc. Vitamin D3 analogs
MXPA04002640A (es) * 2001-09-21 2004-06-07 Hoffmann La Roche Esteres de analogos de 3-desoxi-vitamina d3.
CA2540325A1 (en) * 2003-09-24 2005-04-07 Bioxell Spa Methods for treating bladder dysfunction
JP2007506765A (ja) * 2003-09-24 2007-03-22 ビオクセル エッセ ピ ア １，３−ジアシル化２６，２７−アルキル／ハロアルキルビタミンｄ３化合物及びその使用方法
AU2005216651A1 (en) * 2004-03-01 2005-09-09 Bioxell Spa Treatment of interstitial cystitis with vitamin D compounds

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180293A (zh) * 2010-10-25 2013-06-26 帝人制药株式会社 23-炔-维生素d3衍生物
CN103193695A (zh) * 2013-04-22 2013-07-10 中国药科大学 3-苯基-3-吡咯基戊烷类衍生物及其医药用途
CN103193695B (zh) * 2013-04-22 2015-08-05 中国药科大学 3-苯基-3-吡咯基戊烷类衍生物及其医药用途
CN113274346A (zh) * 2021-05-25 2021-08-20 满孝勇 一种莫匹罗星软膏的应用

Also Published As

Publication number Publication date
IL182145A0 (en) 2007-07-24
JP2008514621A (ja) 2008-05-08
WO2006036813A3 (en) 2006-09-14
US20080318911A1 (en) 2008-12-25
WO2006036813A2 (en) 2006-04-06
EP1797033A2 (en) 2007-06-20
EP1797033A4 (en) 2010-04-28
CA2580962A1 (en) 2006-04-06
ZA200703310B (en) 2008-06-25
AU2005289664A1 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
ZA200703310B (en) 20-Cycloalkyl,26,27-alkyl/haloalkyl vitamin D3 compounds and methods of use thereof
JP2002505668A (ja) 環状エーテルビタミンＤ３化合物、１α（ＯＨ）３−エピ−ビタミンＤ３化合物及びそれらの使用法
NO321925B1 (no) 2-Alkyl-19-nor-vitamin D-forbindelser samt anvendelse derav ved fremstilling av farmasoytiske blandinger og slike blandinger
US20070032461A1 (en) 1,3 Aclyated 24-keto-vitamin d3 compounds and methods of use thereof
US20080064668A1 (en) 1,3-Diacylated, 26,27-Alkyl/Haloakyl Vitamin D3 Compounds and Methods of Use Thereof
JP2002506429A (ja) ３−エピビタミンｄ２化合物及びその使用法
NL8420327A (nl) Isomeren van hydroxyvitamine d2.
US20080280859A1 (en) Gemini vitamin d3 compounds and methods of use thereof
JP2006525367A (ja) ジェミニビタミンｄ３化合物及びその使用方法
US20090298800A1 (en) 1,25-dihydroxy, 20-cyclopropyl,26-27-deuteroalkyl vitamin d3 compounds and methods of use thereof
US9834512B2 (en) (22E)-2-methylene-26,27-cyclo-22-dehydro-1α-hydroxy-19-norvitamin D3 derivatives
US20090099140A1 (en) 20-Alkyl, Gemini Vitamin D3 Compounds and Methods of Use Thereof
EP2640687B1 (en) 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS
JP5449767B2 (ja) １α，２５−ジヒドロキシビタミンＤ３の低血漿カルシウム上昇性１６，２３−ジエン−２５−オキシムアナログ
MX2007011919A (es) 2-metilen-19-nor-(23s)-25-deshidro-1a-hidroxivitamina d3-26,23-lactona y 2-metilen19-nor-(23r)-25-deshidro-1a- hidroxivitamina d3-26,23-lactona.
JP2007506780A (ja) 膀胱機能障害の治療方法
CN101198336A (zh) 20－烷基双生维生素d3化合物及其使用方法
ZA200602385B (en) 1,3-Diacylated,26,27-alkyl/haloalkyl vitamin D3 compounds and methods of use thereof
HK1118475A (en) 20-alkyl, gemini vitamin d3 compounds and methods of use thereof
US20130005686A1 (en) 2-Methylene-(22E)-25-Hexanoyl-24-OXO-26,27-Cyclo-22-Dehydro-19-Nor-Vitamin D Analogs
WO2006035075A1 (en) Use of vitamin d compounds for the prevention or treatment of chronic prostatitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080116